Efficacy of Adefovir dipivoxil for patients with HBeAg positive chronic hepatitis B and its influencing factor

Objective To observe the efficacy of domestic adefovir dipivoxil (ADV) in the treatment of patients with HBeAg positive chronic hepatitis B, and analyze related factors of the curative effect. Methods A total of 118 HBeAg positive chronic hepatitis B patients were collected from 2005 June to 2011 September in our hospital. They were treated with domestic ADV for 48 weeks. The clinical data was collected. The efficacy was observed and the relevance of therapeutic and factors such as ALT level, HBV DNA level, body mass index (BMI) and age before treatment were analyzed. Results After 48 weeks, ALT recovery rate was 88%; HBV DNA negative rate was 43.22%, 22.03% patients’E antigen lost, 18.64% of which occurred E antibody serological conversion, and the resistant rate was 0. The patients with HBV DNA negative conversion had higher baseline ALT levels, lower HBV DNA load, smaller BMI, higher percentage of obtaining Initial virologic response (IVR) at 24 weeks, and they were younger. Conclution Domestic ADV can effectively inhibit HBV DNA replication, improve liver function, and promote HBeAg serological conversion. The patients with lower levels of serum HBV DNA, higher ALT levels, lower BMI. Younger patients has higer efficacy to ADV standard treatment.